Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>
<a href="https://smartkarma.com/entities/axonics-inc">Axonics </a>is a rapidly growing medical technology company that has successfully challenged the long-standing dominance of Medtronic in the sacral neuromodulation (SNM) market.</li>
 <li>The company's key products, the <a href="https://smartkarma.com/entities/axonics-inc">Axonics </a>R20/F15 SNM systems for bladder and bowel dysfunction and the Bulkamid urethral bulking agent, address large and underpenetrated markets, providing a long runway for growth.</li>
 <li>Strong revenue growth and improving margins demonstrate a clear trajectory towards sustained profitability, although the company has a history of net losses.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
Axonics is a rapidly growing medical technology company that has successfully challenged the long-standing dominance of Medtronic in the sacral neuromodulation (SNM) market.
  The company's key products, the Axonics R20/F15 SNM systems for bladder and bowel dysfunction and the Bulkamid urethral bulking agent, address large and underpenetrated markets, providing a long runway for growth.
  Strong revenue growth and improving margins demonstrate a clear trajectory towards sustained profitability, although the company has a history of net losses.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/axonics-inc" target="_blank" data-smartkarma-citation="entities:36996:1" rel="noopener">Axonics (AXNX US)</a> believes that the U.S. sacral neuromodulation market is now worth of ~$800M, which is poised to double over the next five years to $1.6B.</li>
<li>The company has been reporting superior revenue growth since 2020. Axonics raised 2023 revenue guidance to $358M, up 32% YoY. The company has become adjusted EBITDA positive in 2022.</li>
<li>With superior product portfolio in terms of patient satisfaction, longer product life, and smaller size, Axonics is the stronger player in the U.S. duopoly sacral neuromodulation market.</li>
</ul>



Axonics (AXNX US) believes that the U.S. sacral neuromodulation market is now worth of ~$800M, which is poised to double over the next five years to $1.6B.
The company has been reporting superior revenue growth since 2020. Axonics raised 2023 revenue guidance to $358M, up 32% YoY. The company has become adjusted EBITDA positive in 2022.
With superior product portfolio in terms of patient satisfaction, longer product life, and smaller size, Axonics is the stronger player in the U.S. duopoly sacral neuromodulation market.


Axonics (AXNX US): Large Underserved Market And Superior Portfolio Ensure Multi-Year Growth

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>On the 8th of August, <a href="https://www.smartkarma.com/entities/insulet-corp" target="_blank" data-smartkarma-citation="entities:5252:1" rel="noopener">Insulet Corp (PODD US)</a> filed a lawsuit accusing <a href="https://www.smartkarma.com/entities/eoflow-co-ltd" target="_blank" data-smartkarma-citation="entities:36100:1" rel="noopener">Eoflow (294090 KS)</a> of the misappropriation of trade secrets, patent infringement, and trademark dilution.</li>
<li>The filing was pretty heavy on accusations. EOFlow declined ~11% on the news.</li>
<li>Undeterred, <a href="https://www.smartkarma.com/entities/medtronic-plc" target="_blank" data-smartkarma-citation="entities:14982:1" rel="noopener">Medtronic (MDT US)</a> continues to preach all is peachy, suggesting the EOFlow merger is a go, and Medtronic will deal with the lawsuit, as and when.</li>
</ul>


On the 8th of August, Insulet Corp (PODD US) filed a lawsuit accusing Eoflow (294090 KS) of the misappropriation of trade secrets, patent infringement, and trademark dilution.
The filing was pretty heavy on accusations. EOFlow declined ~11% on the news.
Undeterred, Medtronic (MDT US) continues to preach all is peachy, suggesting the EOFlow merger is a go, and Medtronic will deal with the lawsuit, as and when.


United States

Axonics, Inc. operates as a medical technology company. The Company focuses on the design, development, and commercialization of innovative and minimally invasive sacral neuromodulation solutions which used to treat patients with overactive bladder, fecal incontinence, andurinary retention. Axonics serves patients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Axonics (AXNX US)

Primer: Axonics (AXNX US) - Aug 2026

Axonics is a rapidly growing medical technology company that has successfully challenged the long-standing dominance of Medtronic in the sacral...

αSK Primers

Axonics (AXNX US): Large Underserved Market And Superior Portfolio Ensure Multi-Year Growth

Axonics predicts the U.S. sacral neuromodulation market will double to $1.6B in the next five years. The company is reporting strong revenue...

Tina Banerjee

EOFlow/Medtronic: What Lawsuit?

Trading at a 9.9% gross spread, below where it was trading before the lawsuit. On balance, this Offer gets up. But run the deal specifics via a...

David Blennerhassett

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Primer: Axonics (AXNX US) - Aug 2026

Axonics is a rapidly growing medical technology company that has successfully challenged the long-standing dominance of Medtronic in the sacral...

αSK Primers

Axonics (AXNX US): Large Underserved Market And Superior Portfolio Ensure Multi-Year Growth

​Axonics predicts the U.S. sacral neuromodulation market will double to $1.6B in the next five years. The company is reporting strong revenue...

Tina Banerjee

EOFlow/Medtronic: What Lawsuit?

Trading at a 9.9% gross spread, below where it was trading before the lawsuit. On balance, this Offer gets up. But run the deal specifics via a...

David Blennerhassett

Axonics predicts the U.S. sacral neuromodulation market will double to $1.6B in the next five years. The company is reporting strong revenue...